இருமுனை மனச்சோர்வு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Lumateperone is a butyrophenone atypical antipsychotic developed by Intra-Cellular Therapies, licensed from Bristol-Myers Squibb, for the schizophrenia treatment, and currently in development for Bipolar Depression and other neurological indications. The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Applications (sNDAs) for lumateperone to treat depressive episodes associated with bipolar I or II disorder, as monotherapy and as adjunctive therapy with lithium or valproate.  If approved, CAPLYTA has the potential to be a vital medicine for a broad group of patients suffering from these highly prevalent, chronic, complex conditions.  Ketamine Hydrochloride: NeuroRx, Inc. NeuroRx has developed a sequential therapy comprising IV

United statesSumitomo dainippon pharmaLos angelesClexio biosciencesIltoo pharmaBristol myers squibbCelon pharmaDrug administrationNeurorx incBipolar depression treatmentBipolar depressionDepression pipelineBipolar depression pipeline reportIntra cellular therapiesNew drug applicationsPrescription drug user fee act